Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020

Increasingly, cost-effectiveness analyses are being done to determine the value of rapidly increasing oncology drugs; however, this assumes that these analyses are unbiased. To analyze the characteristics of cost-effectiveness studies and to determine characteristics associated with whether an oncol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA network open 2021-11, Vol.4 (11), p.e2135123-e2135123
Hauptverfasser:	Haslam, Alyson, Lythgoe, Mark P, Greenstreet Akman, Emma, Prasad, Vinay
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Conflicts of interest Cost analysis Cost-Benefit Analysis - statistics & numerical data Cost-Benefit Analysis - trends Cross-Sectional Studies Drug Approval - economics Drug Approval - statistics & numerical data Drugs FDA approval Forecasting Funding Humans Neoplasms - drug therapy Oncology Online Only Original Investigation Pharmaceutical industry Retrospective Studies United States United States Food and Drug Administration - statistics & numerical data
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!